Liberum Appointed as Nominated Adviser & Broker

Futura Medical

Appointment of Liberum as Nominated Adviser and Broker

23 May 2019

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces the appointment, with immediate effect, of Liberum Capital Limited ("Liberum") as its Nominated Adviser and sole Broker.

ENDS

For further information please contact:

Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO

Email: [email protected]: +44 (0) 1483 685 670 

Nominated Adviser and Broker:LiberumBidhi Bhoma

Euan Brown

Kane CollingsTel: +44 (0) 20 3100 2000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: [email protected]

Tel: +44 (0) 203 950 9144

Notes to editors

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com